# Memento Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/memento-medicines

- Industry: Biotechnology
- Headquarters: Boston, US
- Total disclosed funding: $38M
- Latest round: Series A (Jun 3, 2026)
- Investors on record: 5

## About

Founded in 2026 and based in Boston, MA, the company's CEO is Naveen Daryani. Memento Medicines, Inc. that provided antibody therapies for retinal diseases. In June 2026, Memento Medicines, Inc. raised USD 38 million in series A funding co-led by  Forbion, RA Capital Management, and Avego, with Sanofi Ventures and Samsara BioCapital.

The company's lead product candidate is MMT-205, a bispecific antibody licensed from MabTics Co., Ltd. and Curacle Co., Ltd.. MMT-205 is designed to simultaneously activate the Tie2 receptor and inhibit VEGF, two clinically validated pathways involved in retinal and vascular diseases. The therapy is intended to improve upon existing anti-VEGF treatments by enhancing retinal vascular stability and potentially delivering improved efficacy and durability. Preclinical studies cited by the company indicate that MMT-205 produced greater Tie2 activation and improved retinal vascular integrity compared with current therapies

The company plans to use the 2026 funding to advance its MMT-205 antibody through preclinical and clinical development studies for retinal diseases.

## Funding rounds

- Series A, Jun 3, 2026, $38M — Forbion, Sanofi Ventures, RA Capital Management, Avego, Samsara BioCapital

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Avego (https://capitalatlas.ai/funds/avego) — Series A
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A